Gemcitabine Intravesical System: A Novel Treatment Option for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) approved the gemcitabine intravesical system, marketed as Inlexzo, on September 9, 2025, for the treatment of adult patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This new therapy is intended for patients with carcinoma in situ, with or without papillary tumors, who are either ineligible for or have declined a radical cystectomy.
Understanding Inlexzo and Its Delivery Method
Inlexzo represents a shift from standard intravesical instillation, where drugs are typically cleared rapidly from the bladder. According to Janssen Biotech, the system uses a drug-eluting silicone insert to provide a continuous, prolonged release of 225 mg of gemcitabine directly into the bladder. This targeted approach is designed to improve drug penetration into the urothelium while reducing the systemic toxicity often associated with broader treatments.
The device is placed during an in-office procedure that does not require general anesthesia. Once inserted, the system remains in the bladder to deliver medication over a 3-week cycle. Patients continue this regimen for up to 6 months, followed by a maintenance phase of one dose every 12 weeks for up to 18 months, or until the disease progresses or unacceptable toxicity occurs.
Before the approval of Inlexzo, clinicians frequently used off-label intravesical aqueous gemcitabine to treat NMIBC. However, this method showed limited efficacy with complete response rates ranging only between 28% and 47%, and durability rarely exceeding one year.
Clinical Trial Performance
The FDA approval of Inlexzo is based on data from cohort 2 of the SunRISe-1 study, an ongoing phase 2b multicenter trial. In this study, 83 adult patients with BCG-unresponsive NMIBC received the treatment. Findings showed that 82% of patients achieved a complete response, meaning no visible signs of cancer remained after treatment. Data indicated that 51% of these patients maintained their complete response at the one-year mark.
Reported adverse events were primarily low-grade, according to trial documentation. Common side effects included urinary symptoms such as frequency, urgency, and dysuria, along with urinary tract infections. Laboratory abnormalities, including changes in hemoglobin, lipase, creatinine, and various liver enzymes, were also observed during the study.
Samantha Carter notes that the significance of this approval lies in the “bladder-sparing” nature of the therapy. For patients facing the prospect of a radical cystectomy—a major surgical intervention—the ability to achieve a sustained response through a localized, in-office device offers a meaningful alternative that directly addresses the trade-off between cancer control and quality of life.
The Role of Pharmacy and Future Outlook
Pharmacists are expected to play a central role in the implementation of this therapy, including managing formulary decisions and coordinating the logistics of the 3-week dosing cycles. Because the device requires specific handling and insertion by a trained provider, pharmacy teams are responsible for confirming product availability and ensuring that treatment schedules are strictly followed to maintain therapeutic efficacy.
Looking ahead, the integration of Inlexzo into clinical practice may signal a broader move toward precision drug-delivery platforms in uro-oncology. As urologists and oncologists gain more experience with the system, the focus will likely remain on long-term patient adherence and the management of potential side effects to maximize the benefits of this bladder-preserving option.
Frequently Asked Questions
Who is the target patient for Inlexzo?
Inlexzo is indicated for adult patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors, who are unable or unwilling to undergo a radical cystectomy.
How does Inlexzo differ from previous gemcitabine treatments?
Unlike traditional off-label gemcitabine, which is rapidly cleared from the bladder, Inlexzo utilizes a drug-eluting silicone insert. This allows for continuous, sustained exposure of the bladder lining to the medication over a 3-week period.
What are the most common side effects associated with this treatment?
The most frequent treatment-related adverse events were low-grade and included urinary frequency, urgency, dysuria, and urinary tract infections, along with various laboratory abnormalities.
How will the shift toward localized, prolonged-release treatments change the way you approach long-term bladder cancer management?